14.98 +0.00 (0.00%)
MAPP
Stock Details
Last Trade:14.98 Change:+0.00 (0.00%) Prev Close:14.98 Open: 15.19 Days Range:14.89 – 15.21 52 Week Range: 1.57 - 16.80 Volume:110074 P/E: N/AEPS:-0.98
View AllRecent Alerts 02/10/10
Recent Alert on 02/02/10 at 9:01am
Lazard Capital Maintains a 'Buy' on MAP Pharmaceuticals (MAPP); Raises Price Target
Lazard Capital Maintains a 'Buy' on MAP Pharmaceuticals (MAPP); Raises Price Target
Lazard Capital maintains a 'Buy' rating on MAP Pharmaceuticals (Nasdaq: MAPP), raises price target from $13 to $18. To see all the upgrades/downgrades on shares of MAPP, visit our Analyst Ratings page. MAP Pharmaceuticals, Inc. uses inhalation... Read More
Recent Alert on 01/11/10 at 12:48pm
Unusual 11 Mid-Day Movers 01/11: PEIX, MMR, MAPP, EXXI, GTCB Higher; CYCC, FMX, LUNA, MED Lower
Unusual 11 Mid-Day Movers 01/11: PEIX, MMR, MAPP, EXXI, GTCB Higher; CYCC, FMX, LUNA, MED Lower
Recent Alert on 01/11/10 at 10:28am
Morning Movers 01/11: PEIX, EPCT, MMR, TUES, KTII Higher; CYCC, LUNA, IOC, ASBC, HOGS Lower
Morning Movers 01/11: PEIX, EPCT, MMR, TUES, KTII Higher; CYCC, LUNA, IOC, ASBC, HOGS Lower
Recent Alert on 01/11/10 at 8:57am
MAP Pharma (MAPP) NOt Rquired by U.S. FDA to Perform Second Pivotal Effecacy for LEVADEX NDA Submission
MAP Pharma (MAPP) NOt Rquired by U.S. FDA to Perform Second Pivotal Effecacy for LEVADEX NDA Submission
Recent Alert on 01/11/10 at 8:57am
MAP Pharma (MAPP) NOt Rquired by U.S. FDA to Perform Second Pivotal Effecacy for LEVADEX NDA Submission
MAP Pharma (MAPP) NOt Rquired by U.S. FDA to Perform Second Pivotal Effecacy for LEVADEX NDA Submission
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 06/02/09 at 11:35am
Analyst upgrades, downgrades and initiations: CAL, NETL, MAPP, DDUP, LMT ...
Analyst upgrades, downgrades and initiations: CAL, NETL, MAPP, DDUP, LMT ...